792 research outputs found
Protein tyrosine kinases regulate agonist-stimulated prostacyclin release but not von Willebrand factor secretion from human umbilical vein endothelial cells
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.
Since the publication of this article [1], it has come to the attention of the authors that information for one of the authors was not included in the competing interests section. Craig Richie has declared potential competing interests with the following companies; Janssen, Eisai, Pfizer, Eli Lilly, Roche Diagnostics, Boeringher Ingleheim, Novartis, AC Immune, Ixico, Aridhia, Amgen, Berry Consultants, Lundbeck, Sanofi, Quintiles (IQVIA) and Takeda. The full competing interests section for this article can be found below
The liver pharmacological and xenobiotic gene response repertoire
We have used a supervised classification approach to systematically mine a large microarray database derived from livers of compound-treated rats. Thirty-four distinct signatures (classifiers) for pharmacological and toxicological end points can be identified. Just 200 genes are sufficient to classify these end points. Signatures were enriched in xenobiotic and immune response genes and contain un-annotated genes, indicating that not all key genes in the liver xenobiotic responses have been characterized. Many signatures with equal classification capabilities but with no gene in common can be derived for the same phenotypic end point. The analysis of the union of all genes present in these signatures can reveal the underlying biology of that end point as illustrated here using liver fibrosis signatures. Our approach using the whole genome and a diverse set of compounds allows a comprehensive view of most pharmacological and toxicological questions and is applicable to other situations such as disease and development
Fractionation of sulfide phases controls the chalcophile metal budget of arc magmas: evidence from the Chilas complex, Kohistan arc, Pakistan
Some arc magmas lead to the formation of porphyry deposits in the relatively shallow upper crust (<5 km). Porphyry deposits are major sources of Cu and an important Au source but lack significant amounts of platinum group elements (PGE). Sulfide phases control the behavior of chalcophile elements and affect the potential to form ore deposits either by remaining in the mantle residue or by fractionating from arc magmas at lower crustal levels, although in detail the role of sulfide saturation in the lower crust remains poorly understood. Lower crustal cumulate rocks from the 85 Ma Chilas Complex of the Kohistan arc, Pakistan, provide insight into processes that occur at depth in arcs. Here we provide Cu, Ni, Au, and PGE concentrations and Os isotope ratios of the Chilas Complex in order to constrain the extent of sulfide saturation in the lower crust and the effect of sulfide saturation on the metal budget of evolved melts that ascend to the upper crust. The Chilas rock suite contains less than 0.17 wt % sulfides and low PGE concentrations. In situ laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) measurements of the sulfide inclusions in silicate minerals show enrichment in several chalcophile elements (up to 34 wt % Cu, 23 ppm Au, 245 ppm Pd, and 20 ppm Pt), whereas iridium group PGE (IPGE- Os, Ir, Ru) are mainly below detection limits. The metal content of the parental melt was modeled based on the elemental concentrations of the sulfides. The modeled parental arc magmas contain 70 to 140 ppm Cu, 0.2 to 1.5 ppb Au, and 1.2 to 8 ppb Pd, but low concentrations of IPGE, suggesting that IPGE were likely retained in the mantle source. Mass balance calculations show that segregation of a sulfide melt in the lower crust could further deplete the melt by more than 95% in Pd and Pt, 33 to 85% in Au, and 13 to 60% in Cu. Thus, magmas that ascend to the upper crust would contain very low concentrations of Au (< 0.2 ppb) and Pd (< 0.04 ppb), but they would retain sufficient concentration of Cu (~45–57 ppm) to form porphyry Cu deposits upon emplacement in the upper crust, as is commonly observed in arc settings
The differential hormonal milieu of morning versus evening, may have an impact on muscle hypertrophic potential
Substantial gains in muscle strength and hypertrophy are clearly associated with the routine performance of resistance training. What is less evident is the optimal timing of the resistance training stimulus to elicit these significant functional and structural skeletal muscle changes. Therefore, this investigation determined the impact of a single bout of resistance training performed either in the morning or evening upon acute anabolic signalling (insulin-like growth factor-binding protein-3 (IGFBP-3), myogenic index and differentiation) and catabolic processes (cortisol). Twenty-four male participants (age 21.4±1.9yrs, mass 83.7±13.7kg) with no sustained resistance training experience were allocated to a resistance exercise group (REP). Sixteen of the 24 participants were randomly selected to perform an additional non-exercising control group (CP) protocol. REP performed two bouts of resistance exercise (80% 1RM) in the morning (AM: 0800 hrs) and evening (PM: 1800 hrs), with the sessions separated by a minimum of 72 hours. Venous blood was collected immediately prior to, and 5 min after, each resistance exercise and control sessions. Serum cortisol and IGFBP-3 levels, myogenic index, myotube width, were determined at each sampling period. All data are reported as mean ± SEM, statistical significance was set at P≤0.05. As expected a significant reduction in evening cortisol concentration was observed at pre (AM: 98.4±10.5, PM: 49.8±4.4 ng/ml, P0.05). Timing of resistance training regimen in the evening appears to augment some markers of hypertrophic potential, with elevated IGFBP-3, suppressed cortisol and a superior cellular environment. Further investigation, to further elucidate the time course of peak anabolic signalling in morning vs evening training conditions, are timely
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen
A large scale hearing loss screen reveals an extensive unexplored genetic landscape for auditory dysfunction
The developmental and physiological complexity of the auditory system is likely reflected in the underlying set of genes involved in auditory function. In humans, over 150 non-syndromic loci have been identified, and there are more than 400 human genetic syndromes with a hearing loss component. Over 100 non-syndromic hearing loss genes have been identified in mouse and human, but we remain ignorant of the full extent of the genetic landscape involved in auditory dysfunction. As part of the International Mouse Phenotyping Consortium, we undertook a hearing loss screen in a cohort of 3006 mouse knockout strains. In total, we identify 67 candidate hearing loss genes. We detect known hearing loss genes, but the vast majority, 52, of the candidate genes were novel. Our analysis reveals a large and unexplored genetic landscape involved with auditory function
Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers
ATRX (alpha thalassemia/mental retardation X-linked) complexes with DAXX to deposit histone variant H3.3 into repetitive heterochromatin. Recent genome sequencing studies in cancers have revealed mutations in ATRX and their association with ALT (alternative lengthening of telomeres) activation. Here we report depletion of ATRX in mouse ES cells leads to selective loss in ribosomal RNA gene (rDNA) copy number. Supporting this, ATRX-mutated human ALT-positive tumors also show a substantially lower rDNA copy than ALT-negative tumors. Further investigation shows that the rDNA copy loss and repeat instability are caused by a disruption in H3.3 deposition and thus a failure in heterochromatin formation at rDNA repeats in the absence of ATRX. We also find that ATRX-depleted cells are reduced in ribosomal RNA transcription output and show increased sensitivity to RNA polymerase I (Pol I) transcription inhibitor CX5461. In addition, human ALT-positive cancer cell lines are also more sensitive to CX5461 treatment. Our study provides insights into the contribution of ATRX loss of function to tumorigenesis through the loss of rDNA stability and suggests the therapeutic potential of targeting Pol I transcription in ALT cancers.This work was supported by
the Norwegian Cancer Society and the Research Council of Norway (to P.C.); an
Australia Research Council Future Fellowship award (to L.H.W.); National Health
and Medical Research Council Program Grant 1053792 (to R.B.P. and R.D.H.),
senior research fellowships (to R.B.P. and R.D.H.), and a project grant (to L.H.W.);
and a Cure Brain Cancer Foundation Australia project grant (to L.H.W. and H.P.J.V.)
When One Size Does Not Fit All: A Simple Statistical Method to Deal with Across-Individual Variations of Effects
In science, it is a common experience to discover that although the investigated effect is very clear in some individuals, statistical tests are not significant because the effect is null or even opposite in other individuals. Indeed, t-tests, Anovas and linear regressions compare the average effect with respect to its inter-individual variability, so that they can fail to evidence a factor that has a high effect in many individuals (with respect to the intra-individual variability). In such paradoxical situations, statistical tools are at odds with the researcher’s aim to uncover any factor that affects individual behavior, and not only those with stereotypical effects. In order to go beyond the reductive and sometimes illusory description of the average behavior, we propose a simple statistical method: applying a Kolmogorov-Smirnov test to assess whether the distribution of p-values provided by individual tests is significantly biased towards zero. Using Monte-Carlo studies, we assess the power of this two-step procedure with respect to RM Anova and multilevel mixed-effect analyses, and probe its robustness when individual data violate the assumption of normality and homoscedasticity. We find that the method is powerful and robust even with small sample sizes for which multilevel methods reach their limits. In contrast to existing methods for combining p-values, the Kolmogorov-Smirnov test has unique resistance to outlier individuals: it cannot yield significance based on a high effect in one or two exceptional individuals, which allows drawing valid population inferences. The simplicity and ease of use of our method facilitates the identification of factors that would otherwise be overlooked because they affect individual behavior in significant but variable ways, and its power and reliability with small sample sizes (<30–50 individuals) suggest it as a tool of choice in exploratory studies
A stubbornly large mass of cold dust in the ejecta of Supernova 1987A
We present new Herschel photometric and spectroscopic observations of
Supernova 1987A, carried out in 2012. Our dedicated photometric measurements
provide new 70 micron data and improved imaging quality at 100 and 160 micron
compared to previous observations in 2010. Our Herschel spectra show only weak
CO line emission, and provide an upper limit for the 63 micron [O I] line flux,
eliminating the possibility that line contaminations distort the previously
estimated dust mass. The far-infrared spectral energy distribution (SED) is
well fitted by thermal emission from cold dust. The newly measured 70 micron
flux constrains the dust temperature, limiting it to nearly a single
temperature. The far-infrared emission can be fitted by 0.5+-0.1 Msun of
amorphous carbon, about a factor of two larger than the current nucleosynthetic
mass prediction for carbon. The observation of SiO molecules at early and late
phases suggests that silicates may also have formed and we could fit the SED
with a combination of 0.3 Msun of amorphous carbon and 0.5 Msun of silicates,
totalling 0.8 Msun of dust. Our analysis thus supports the presence of a large
dust reservoir in the ejecta of SN 1987A. The inferred dust mass suggests that
supernovae can be an important source of dust in the interstellar medium, from
local to high-redshift galaxies.Comment: ApJ accepted, 8 page
- …